Abstract
Aurora kinases are essential for the regulation of chromosome segregation and cytokinesis during mitosis and play a role in tumorigenesis and tumor progression in humans. Aurora kinase A and Aurora kinase B are overexpressed in some gynecologic cancers, and their overexpression is associated with poor prognosis. Thus, targeting of Aurora kinases has become an attractive strategy for pharmaceutical companies, who have developed more than 30 Aurora kinase inhibitors for treatment of cancers. Some of these inhibitors have been shown to be effective in targeted therapies for human cancer, and others are currently being investigated. In this review, we summarize the most recent advances in preclinical studies and clinical trials of patented Aurora kinase inhibitors for gynecologic tumors.
Keywords: Gynecologic malignancies, Aurora kinases, Aurora kinase inhibitors
Recent Patents on Anti-Cancer Drug Discovery
Title: Update on Aurora Kinase Inhibitors in Gynecologic Malignancies
Volume: 3 Issue: 3
Author(s): Xia Tao, Hye S. Chon, Siqing Fu, John J. Kavanagh and Wei Hu
Affiliation:
Keywords: Gynecologic malignancies, Aurora kinases, Aurora kinase inhibitors
Abstract: Aurora kinases are essential for the regulation of chromosome segregation and cytokinesis during mitosis and play a role in tumorigenesis and tumor progression in humans. Aurora kinase A and Aurora kinase B are overexpressed in some gynecologic cancers, and their overexpression is associated with poor prognosis. Thus, targeting of Aurora kinases has become an attractive strategy for pharmaceutical companies, who have developed more than 30 Aurora kinase inhibitors for treatment of cancers. Some of these inhibitors have been shown to be effective in targeted therapies for human cancer, and others are currently being investigated. In this review, we summarize the most recent advances in preclinical studies and clinical trials of patented Aurora kinase inhibitors for gynecologic tumors.
Export Options
About this article
Cite this article as:
Tao Xia, Chon S. Hye, Fu Siqing, Kavanagh J. John and Hu Wei, Update on Aurora Kinase Inhibitors in Gynecologic Malignancies, Recent Patents on Anti-Cancer Drug Discovery 2008; 3 (3) . https://dx.doi.org/10.2174/157489208786242322
DOI https://dx.doi.org/10.2174/157489208786242322 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Editorial (Hot Topic: Cross-Talking Metabolism and Epigenetics in Anti-Cancer Drug Design)
Current Pharmaceutical Design Mitochondria-targeted Antioxidants as a Prospective Therapeutic Strategy for Multiple Sclerosis
Current Medicinal Chemistry Anthocyanins: Plant Pigments, Food Ingredients or Therapeutic Agents for the CNS? A Mini-Review Focused on Clinical Trials
Current Pharmaceutical Design (Review Article) Screening for Disease-Markers and Investigating Drug Effects by Proteome Profiling: Can it Meet Expectations?
Combinatorial Chemistry & High Throughput Screening Circulating Exosomes as Potential Biomarkers in Cardiovascular Disease
Current Pharmaceutical Design Transbronchial Needle Aspiration (TBNA): Past Present and Future
Current Respiratory Medicine Reviews Pisosterol Induces G2/M Cell Cycle Arrest and Apoptosis via the ATM/ATR Signaling Pathway in Human Glioma Cells
Anti-Cancer Agents in Medicinal Chemistry Breaking the DNA Damage Response via Serine/Threonine Kinase Inhibitors to Improve Cancer Treatment
Current Medicinal Chemistry An Overview of Targeted Alpha Therapy with <sup>225</sup>Actinium and <sup>213</sup>Bismuth
Current Radiopharmaceuticals Chitosan in Biomedical Engineering: A Critical Review
Current Stem Cell Research & Therapy Black Tea Polyphenols-Mediated In Vivo Cellular Responses During Carcinogenesis
Mini-Reviews in Medicinal Chemistry Synthesis, Cytotoxicity and Antimicrobial Activity of New Enmein-type Kauranoid Diterpenoid Derivatives
Anti-Cancer Agents in Medicinal Chemistry Comparative Analysis of Fruit and Vegetable Consumption in a Food Service Unit: Is it Possible to Influence the Choices?
The Natural Products Journal MicroRNAs and the Warburg Effect: New Players in an Old Arena
Current Gene Therapy Carbohydrate-Based Bioactive Compounds for Medicinal Chemistry Applications
Mini-Reviews in Medicinal Chemistry Bioavailability and Pharmacokinetics of Genistein: Mechanistic Studies on its ADME
Anti-Cancer Agents in Medicinal Chemistry Green Synthesis and Antioxidant Activity of Novel γ-Cyano-α- hydroxyphosphonate Derivatives
Medicinal Chemistry Editorial (Thematic Issues: New Developments in the Medicinal Chemistry of Some Azoles)
Current Topics in Medicinal Chemistry Developments in High-Yield System Expressed Vaccines and Immunotherapy
Recent Patents on Biotechnology Molecular Mechanisms and Targeted Therapies Including Immunotherapy for Non-Small Cell Lung Cancer
Current Cancer Drug Targets